Black porous silicon nanoparticles (BPSi NPs) are known as highly efficient infrared light absorbers that are well-suitable for photothermal therapy (PTT) and photoacoustic imaging (PAI). PTT and PAI require a sufficient number of effectively light-absorbing NPs to be accumulated in tumor after intravenous administration. Herein, biodistribution of PEGylated BPSi NPs with different sizes (i.e., 140, 200, and 300 nm in diameter) is investigated after intravenous administration in mice. BPSi NPs were conjugated with fluorescent dyes Cy5.5 and Cy7.5 to track them in vitro and in vivo, respectively. Optical imaging with an in vivo imaging system (IVIS) was found to be an inadequate technique to assess the biodistribution of the dye-labeled BPSi NPs in vivo because the intrinsic strong absorbance of the BPSi NPs interfered fluorescence detection. This challenge was resolved via the use of inductively coupled plasma optical emission spectrometry to analyze ex vivo the silicon content in different tissues and tumors. The results indicated that most of the polyethylene glycol-coated BPSi NPs were found to accumulate in the liver and spleen after intravenous injection. The smallest 140 nm particles accumulated the most in tumors at an amount of 9.5 ± 3.4% of the injected dose (concentration of 0.18 ± 0.08 mg/mL), the amount known to produce sufficient heat for cancer PTT. Furthermore, the findings from the present study also suggest that techniques other than optical imaging should be considered to study the organ biodistribution of NPs with strong light absorbance properties.
Black porous silicon nanoparticles (BPSi NPs) are known as highly efficient infrared light absorbers that are well-suitable for photothermal therapy (PTT) and photoacoustic imaging (PAI). PTT and PAI require a sufficient number of effectively light-absorbing NPs to be accumulated in tumor after intravenous administration. Herein, biodistribution of PEGylated BPSi NPs with different sizes (i.e., 140, 200, and 300 nm in diameter) is investigated after intravenous administration in mice. BPSi NPs were conjugated with fluorescent dyes Cy5.5 and Cy7.5 to track them in vitro and in vivo, respectively. Optical imaging with an in vivo imaging system (IVIS) was found to be an inadequate technique to assess the biodistribution of the dye-labeled BPSi NPs in vivo because the intrinsic strong absorbance of the BPSi NPs interfered fluorescence detection. This challenge was resolved via the use of inductively coupled plasma optical emission spectrometry to analyze ex vivo the silicon content in different tissues and tumors. The results indicated that most of the polyethylene glycol-coated BPSi NPs were found to accumulate in the liver and spleen after intravenous injection. The smallest 140 nm particles accumulated the most in tumors at an amount of 9.5 ± 3.4% of the injected dose (concentration of 0.18 ± 0.08 mg/mL), the amount known to produce sufficient heat for cancer PTT. Furthermore, the findings from the present study also suggest that techniques other than optical imaging should be considered to study the organ biodistribution of NPs with strong light absorbance properties.
An efficient and safe
cancer treatment with nanomedicines should
ideally exhibit preferential tumor accumulation, thus lowering the
administration dose and reducing side effects in healthy organs at
the same time.[1] Effective accumulation
in tumors is particularly important for the treatment modalities that
rely on external triggers, such as magnetic hyperthermia[2] and hyperthermia induced by radiofrequency radiation,[3−5] ultrasound,[6,7] or light [photothermal therapy
(PTT)].[8] The latter one especially relies
on the effective accumulation because the penetration depth of light
is rather limited even in the most transparent near-infrared window
in biological tissues.There are two main approaches to direct
nanoparticles (NPs) to
tumors. The first one, active targeting, relies on the surface modifications
of NPs to target specific receptors expressed by tumor cells. Strategies
include modification of the NP surface with targeting antibody, aptamer,
and ligand molecules to achieve specific accumulation in tumors.[9] The exposed targeting moieties, however, can
be hidden under a layer of protein coronas due to opsonization of
NPs.[10] The opsonization may render the
targeting ability of the moieties and additionally increase the recognition
of NPs by the immune system with subsequent clearance. Furthermore,
targeting moieties themselves can be recognized as foreign bodies
and cleared from the blood. Recently, active targeting has been questioned[11] and it has been demonstrated that active targeting
shows insignificant benefit compared to passive targeting.[12]The second approach, passive targeting,
is based on the enhanced
permeability and retention (EPR)[13] effect
of increased vascular permeability for tumors that develop leaky blood
vessel endothelium. To achieve high tumor accumulation by the EPR
effect, NPs have to circulate in blood as long as possible and to
be small enough for extravasation into tumor. The long systemic presence
is most commonly realized with polyethylene glycol (PEG) coatings,[10] which reduces opsonization and prolongs blood
circulation time for hours compared to uncoated NPs.[14] Size dependence of tumor accumulation was observed for
PEG-coated spherical gold,[15,16] polymeric,[17,18] and silica NPs.[19,20] The general trend for all types
of the NPs is that with the decrease in size, the tumor accumulation
is increased. Additionally, shape was proposed to influence the tumor
availability of porous silicon microparticles.[21]Black porous silicon (BPSi) is a new type of photothermal
conversion
agent with strong light absorption. Compared with other inorganic
counterparts, such as Au, graphene, and CuS, the BPSi NPs have unique
features of high surface area, large pore volume, and excellent biocompatibility.[22,23] The BPSi NPs have been applied in PTT[24] and photoacoustic tomography.[25] We have
previously demonstrated the feasibility of BPSi NPs for cancer PTT
following intratumoral injection.[24] However,
the biodistribution of the BPSi NPs after intravenous injection was
still unrevealed. In the present study, we investigate their size-dependent
biological behavior in vitro and in vivo. The effects of the different particle sizes (i.e., 140, 200, and
300 nm in diameter) and surface modifications of BPSi NPs on their
cellular uptake and biocompatibility were investigated in
vitro. We further studied their organ biodistribution and
passive tumor targeting (syngeneic CT26 tumor model) in vivo qualitatively with optical imaging and quantitatively with inductively
coupled plasma-optical emission mass spectrometry (ICP-OES MS) analysis
after intravenous injection.
Experimental Section
Preparation
of the NPs and Surface Modifications
The
BPSi NPs were prepared with the method developed before.[24] After the preparation, the surface of BPSi NPs
is hydrogen-terminated. To make it hydrophilic and enable further
modification, the surface of NPs was oxidized by immersing 20 mg of
them into 30 mL of HCl/H2O2/H2O (volume
ratio: 1/1/5) solution to produce surface −OH groups. The solution
was stirred and kept at 90 °C for 30 min, after which the particles
were rinsed with water and ethanol by repeating high speed centrifugation
and sonication–redispersion steps three times before final
storage in ethanol. The obtained oxidized NPs were noted as BPSi-OH.
Next, BPSi-OH NPs were functionalized with amine groups with (3-aminopropyl)
triethoxysilane (APTES, Acros Organics BVBA, China, 99%) to which
cyanine dye (Cy5.5-NHS or Cy7.5-NHS, Lumiprobe GmbH, Germany) was
conjugated via the reaction between NHS and the amine group. To do
that, 0.25 mg of either Cy5.5-NHS or Cy7.5-NHS was first dispersed
in 0.5 mL of ethanol by sonication. Then, 13 mg of BPSi-OH NPs dispersed
in 1 mL of ethanol was placed into a 20 mL glass vial, followed by
pouring the dye solution. Finally, 10 μL of APTES was added
and the mixture was stirred for 40 min at 65 °C. The vial was
kept closed to prevent ethanol evaporation. The resulting BPSi-Cy5.5/Cy7.5
NPs were washed with ethanol three times. The residual amine groups
were capped by the reaction of BPSi-Cy5.5/Cy7.5 NPs with 20 mg of
succinic anhydride (referred as COOH-BPSi-Cy5.5/Cy7.5) in 2 mL of
ethanol for 16 h at room temperature. Finally, the NPs were functionalized
with two different PEG molecules (PEG 2.0 kDa and PEG 0.5 kDa, Hunan
Huateng Pharmaceutical Co. Ltd., China and Gelest Inc., USA, respectively)
as described before[26] and referred to as
PEG-BPSi-Cy5.5/Cy7.5. Briefly, for 13 mg of BPSi-Cy5.5/Cy7.5 NPs,
130 mg of PEG 2.0 kDa was first dissolved in 1.5 mg of anhydrous toluene
by sonication and subsequently poured into an Erlenmeyer flask. Under
stirring, 260 μL of PEG 0.5 kDa was then added to the flask,
followed by the NP dispersion in 2 mL of ethanol. Afterwards, the
flask was heated to 65 °C with a N2 flow for 20 min
to evaporate ethanol, and subsequently, additional 2 mL of toluene
was added into the flask, which was then sealed and left for 18 h
for PEG molecules to react with −OH groups on the surface of
BPSi-Cy5.5/Cy7.5 NPs. Finally, toluene was evaporated with N2 for 20 min and PEG-BPSi-Cy5.5/Cy7.5 was washed three times with
ethanol to remove unreacted PEGs and stored in the fridge.
Size Separation
To study the effect of different diameters,
the NPs were centrifuged at different speeds after surface modifications
to get a mean diameter of 140, 200, and 300 nm. First, the mixture
of all sizes was centrifuged in ethanol for 20 min at 3000 g in water to separate the 140 nm NPs that stayed in the
supernatant. Afterward, the sediment was resuspended in ethanol by
sonication and centrifuged for 15 min at 1200 g to
separate 200 nm NPs. Finally, large particles were precipitated by
2 min centrifugation at 300 g. The NPs that stayed
in the suspension were then around 300 nm. Each centrifugation was
repeated 2–3 times to ensure that most of the NPs of a certain
size were collected.
Characterization
Transmission Electron Microscopy
Transmission electron
microscopy (TEM) images were acquired with JEOL JEM-2100F (JEOL Ltd.,
Japan) after drying a 2.5 μL drop of PEG-BPSi-Cy7.5 dispersed
in ethanol on a 400 mesh carbon-coated copper grid (Agar Scientific
Ltd., UK).
UV–Vis–NIR Absorption
Light absorption
measurements in the range of 400–900 nm were performed using
a Jasko V-530 (Jasko, Japan) instrument at a high scanning rate. One
milliliter of BPSi-OH water suspension (0.05 mg/mL) was placed into
a quartz cuvette; water was used as the background.
Surface Modifications
Surface modifications were studied
with Fourier transform infrared spectroscopy (FTIR, Thermo Nicolet
iS50, Thermo Fisher Scientific Inc., USA) and thermogravimetric analysis
(TGA, NETZSCH TG 209F1 Libra, Netzsch Holding, Germany). TGA was performed
under 20 mL/min N2 flow to avoid oxidation using the following
sequence: (1) ramp 20 K/min to 80 °C; (2) keep 20 min at 80 °C
to evaporate water; and (3) ramp 20 K/min to 900 °C. The surface
modifications of organic compounds such as APTES and PEG were decomposed
and evaporated during heating in a N2 atmosphere, while
the inorganic porous silicon was kept. Thus, the mass losses for the
NPs from different stages of surface modifications were compared to
determine the amount of conjugated APTES, dye, PEGs, and −COOH
groups.
Colloidal Stability
For colloidal stability studies,
0.1 mg/mL suspensions were incubated at 37 °C in deionized water,
5% mannitol solution (d-mannitol, Sigma-Aldrich, France),
and 1:1 phosphate-buffered saline (PBS)/plasma solution (volume ratio).
At selected time points, 0.1 mL of particle suspension was diluted
with 0.9 mL of water to measure size distributions and ζ potential
using a ZetaSizer Nano ZS (Malvern Panalytical Ltd., UK) instrument.
The same instrument was used to determine particle sizes right after
size separations by centrifuging. The number of particles for each
of the three particle sizes was analyzed using NP tracking analysis
(NanoSight LM10, Malvern Panalytical Ltd., UK). Water suspensions
of PEG-BPSi-Cy7.5 at 0.2 μg/mL were measured three times, and
the average number of particles was calculated.The appearance
of aggregates for the NPs without PEG coating was additionally visualized
by TEM imaging performed using JEOL JEM-2100F. Herein, NPs were dispersed
in 50 mM pH 7.0 PBS buffer (VWR chemicals) at a concentration of 0.5
mg/mL and subsequently incubated in 37 °C for 4 h. 4 h time point
was selected to observe the aggregation difference between BPSi-NH2-Cy5.5 and COOH-BPSi-Cy5.5. After 4 h of incubation, 100 μL
of suspension was slowly dropped on 400 mesh holy carbon copper TEM
grid (Agar Scientific Ltd., UK) located on a paper tissue which consumed
all the excess liquid. The grid was then kept for 5 min to dry.
In Vitro Evaluation
Cell Internalization
Internalization experiments were
studied with CT26 mouse colon cancer cells and RAW 264.7 mouse macrophage
cells. Twenty thousand CT26 or RAW 264.7 cells were cultured on 8-well
plates (Ibidi μ-Slide 8 Well for confocal microscopy) in 0.2
ml of RPMI 1640 or DMEM (Biowest SAS, France) medium, respectively.
After the 24 h incubation for cell attachment, the cells were washed
with 0.2 mL of PBS buffer solution and with 0.2 mL of cell medium.
Then, BPSi-NH2-Cy5.5, COOH-BPSi-Cy5.5, and PEG-BPSi-Cy5.5, dispersed
in 0.2 mL of cell culture medium, were added into each well at 0.05
mg/mL final concentration. Cells were washed twice with buffer solution
(Hank’s Balanced Salt Solution, Biowest SAS, France) after
the incubation at 37 °C for 24 h. Then, cell membranes were stained
with CellMask Green (Thermo Fisher Scientific Inc., USA) at a concentration
of 1 μg/mL for 8 min. After that, they were washed with buffer
solution and cell medium to remove free dye. The internalization of
the NPs was inspected with a Zeiss LSM 700 (Zeiss Group, Germany)
laser scanning confocal microscope with two channels for Cy 5.5 and
CellMask Green.The aggregation and internalization of 140 nm
NPs into CT26 cells was further examined using TEM imaging. A total
of 10,000 CT26 cells per well were attached to the bottom of a 24-well
plate by 24 h of incubation. Then, BPSi-NH2-Cy5.5, COOH-BPSi-Cy5.5,
and PEG-BPSi-Cy5.5 at a concentration of 0.05 mg/mL were added to
cells and incubated for 24 h. Finally, the noninternalized NPs were
removed from cells by washing once with cell medium and fixed in epoxy
resin. The fixation was performed according to the following protocol.
Cells in the well plate were first fixed with 2% glutaraldehyde in
0.1 M phosphate buffer (pH 7.4) for 1 h at RT, followed by 2 ×
5 min wash in 0.1 M phosphate buffer (pH 7.4). Cells were then postfixed
with 1% osmiumtetraoxide in 0.1 M phosphate buffer (pH 7.4) for 1
h at RT, followed by 2 × 5 min wash in 0.1 M phosphate buffer
(pH 7.4). Next, cells were dehydrated in 70% ethanol for 5 min, followed
by 90% ethanol for 5 min, and then in 94% ethanol and absolute ethanol
for 2 × 5 min. After that, epoxy resin infiltration was performed
for 2 h in the 1:1 mixture of Epon and absolute ethanol with subsequent
removal of the mixture. Finally, Beem capsules filled with Epon were
placed on top of the cells; they were incubated for 2 h at RT for
further infiltration of Epon, followed by 24 h polymerization at 60
°C. The polymerized block was snapped out of the well by bending
and sliced to 60 nm ultrathin sections at different depths. The slices
were then placed on TEM grid for imaging.
Viability
Cell
viability experiments were used to study
cytotoxicity of CT26 cancer cells exposed to BPSi NPs with different
particle sizes and surface coatings. To enhance the cell attachment
on the 96-well plate, the surface of the plate was coated with poly-l-lysine solution (0.01%). Poly-l-lysine solution (25
μL) was added to the bottom of the wells and let to dry in an
incubator (37 °C) for 2 h. The wells were washed one time with
0.1 mL of PBS buffer solution, and then, cells (5000 cells/well) were added for cell culture. The cells
were grown for 48 h to attach the cells on the bottom of the wells.
The NPs with different surface coatings (BPSi-NH2-Cy5.5, COOH-BPSi-Cy5.5,
and PEG-BPSi-Cy5.5) and sizes (140, 200, and 300 nm) were washed with
deionized H2O and then dispersed in cell culture medium
at four different concentrations (0.05, 0.1, 0.2, and 0.5 mg/mL).
A total of 0.1 mL of each sample was added into each well (n = 4) and they were incubated for 24 h. Then, the cells
were washed once with the medium and incubated with fresh medium for
another 24 h. Cells incubated in fresh medium or treated with 0.1
mL of 1% of Triton X-100 were used as positive and negative controls,
respectively, for the same period of time. At the end, the cells were
washed with buffer solution and cell culture medium. The cell viability
was measured with CellTiter-Glo assay (Promega Inc., USA) according
to the manufacturer’s instructions using a Victor3 (PerkinElmer
Inc., USA) device.
In Vivo Studies in CT26
Tumor-Bearing Mice
In vivo organ biodistribution
and biocompatibility
studies were performed under the authority of project and personal
licenses granted by the UK Home Office and the UKCCCR Guidelines (1998).
Tumors were established by subcutaneously injecting CT26 cells (1
× 106 cells) at the lower flanks (left and right)
of female BALB/c mice (2 tumors per animal). After 12 days of tumor
growth, animals were divided into five groups (three mice per group):
control, free Cy7.5 dye, and PEG-BPSi-Cy7.5 of three different sizes
(140, 200, and 300 nm in diameter). For the PEG-BPSi-Cy7.5 groups,
mice received i.v. injection of the NPs (5 mg/mouse) suspended in
5% mannitol solution. For the control and free dye groups, mice were
injected with 5% mannitol solution or Cy7.5 (0.015 mg/mouse) suspended
in 5% mannitol solution, respectively. 5% mannitol solution is approximately
isotonic and suitable for intravenous injection alone or with other
medications. Furthermore, this solution does not induce fast aggregation
of NPs compared to, for example, saline or PBS. Fluorescence imaging
was performed at 1, 4, and 24 h postinjection using an IVIS Lumina
III in vivo imaging system (PerkinElmer Inc., USA).
After 24 h, animals were sacrificed and selected vital organs (brain,
heart, lung, liver, spleen, kidney, stomach, intestine, and tumors)
were excised for ex vivo imaging. The analysis of
PEG-BPSi-Cy7.5 NPs ex vivo was then performed using
IVIS software. The appropriate regions of interest (ROIs) that surround
the organs were drawn using the hand, after which the software calculated
the total radiant efficiency for each ROI. Thus, the total radiant
efficiency is proportional both to the surface area of the organ in
the image (area of ROI) and to the fluorescence signal from each pixel
in the ROI. Finally, parts of the organs and tumors were fixed in
10% neutral buffered formalin for histological assessment. After fixing,
samples were wax-embedded and sectioned for hematoxylin and eosin
(H&E) or neutral red staining according to standard histological
protocols at the Royal Veterinary College, UK. All stained sections
were analyzed using a Leica DM 1000 LED Microscope (Leica Microsystems,
UK) coupled with a CDD digital camera (Qimaging, UK).
ICP-OES Analysis
of Si Content
Si content in major
organs (liver, spleen, kidney, lung, and tumor) was quantified by
ICP-OES. First, empty microwave vessels were acid-washed in the microwave
oven with 5 mL of HF and 3 mL of HNO3 to remove possible
Si contaminations. Then, organs were transferred to the vessels and
sample masses were recorded. A total of 5 mL of nitric acid (Fisher,
TraceMetal Grade, 67–69%, Thermo Fisher Scientific Inc., USA)
and 3 mL of hydrogen peroxide (Merck, perhydrol for analysis, 30%,
Merck Group, Germany) were added. The samples were allowed to react
for 30 min. Then, 0.1 mL of HF (Merck, Suprapur, 40%, Merck Group,
Germany) was added. The two-phase microwave-assisted digestion was
carried out in a CEM Mars 5× microwave oven using a preinstalled
digestion program following the EPA3052-standard: (1) ramp to 170
°C for 4 min 30 s; (2) ramp to 180 °C for 3 min 30 s; and
(3) hold for 9 min 30 s. After the samples had cooled down, 1 mL of
4% boric acid (previously prepared) was added and a second microwave
digestion phase was carried out using the following program: (1) ramp
to 170 °C for 15 min and (2) hold for 10 min. Then, 0.5 mL of
an internal standard mixture (Y, Sc, and Au) was added to each sample
and the samples were diluted to 25 mL.The analyses were carried
out using Agilent 5110 VDV ICP-OES. To measure Si content, the data
were taken from emission lines of 288.158 and 250.690 nm. A Sc wavelength
of 361.383 nm was used as an internal standard. Quality control standards
and blanks were used to ensure the reliability of the results.
Statistical
Analysis
Statistical significance (p <
0.05 marked with *, p < 0.01
as **, and p < 0.001 as ***) between groups was
calculated using an unpaired two-tailed Student’s t-test.
Results and Discussion
The BPSi
NPs produced by the reaction of NaSi with NH4Br under an
inert atmosphere[24] after treatment
with HF and milling were predominantly covered by hydrophobic Si–H
bonds. To enable further surface functionalization, the NPs were oxidized
with HCl and hydrogen peroxide[27] to obtain
BPSi-OH NPs with surface −OH groups. BPSi-OH NPs were then
functionalized with amine groups to graft Cy5.5 or Cy7.5 dyes and
PEG of two sizes: 0.5 and 2 kDa (Figure ). The use of two PEG sizes ensured efficient
coverage to enhance biocompatibility and prolong colloidal stability
upon systemic administration.[14,26] The conjugation of
the dye to APTES typically left many APTES amine groups unreacted,
resulting in strong positive ζ-potentials even after PEG coating
(Tables and S1, Supporting Information). Positive ζ potential
in turn led to fast aggregation even of the PEGylated NPs in PBS.
Therefore, unreacted amine groups were capped with succinic anhydrite
to switch ζ potential from positive to negative values, as depicted
in Figure .
Figure 1
Scheme of BPSi-OH
NP surface functionalization with cyanine 5.5
or 7.5 dyes and two differently sized PEG molecules. Free −NH2 groups were capped with succinic anhydrite to reduce ζ
potential and improve colloidal stability.
Table 1
Particle Diameters and ζ Potentials
of BPSi NPs with Different Coatingsa
Particles
size (nm)
PDI
ζ potential (mV)
BPSi-NH2-Cy7.5
140
135 ± 34
0.101
51.3 ± 12.1
180
180 ± 63
0.096
42.7 ± 13.8
300
295 ± 73
0.124
42.6 ± 14.6
COOH-BPSi-Cy7.5
140
80 ± 31
0.117
–50.6 ± 10.8
180
180 ± 63
0.098
–48.1 ± 10.3
300
286 ± 89
0.107
–49.9 ± 11.3
PEG-BPSi-Cy7.5
140
140 ± 54
0.11
4.1 ± 6.7
200
195 ± 62
0.107
3.9 ± 6.5
300
308 ± 97
0.107
–4.6 ± 8.1
n = 3, ±value
is SD.
Scheme of BPSi-OH
NP surface functionalization with cyanine 5.5
or 7.5 dyes and two differently sized PEG molecules. Free −NH2 groups were capped with succinic anhydrite to reduce ζ
potential and improve colloidal stability.n = 3, ±value
is SD.Representative TEM
images of PEG-BPSi-Cy5.5 particles are shown
in Figure a. NPs were
prepared by ball milling of the larger microparticles obtained after
the NaSi reduction, and they presented irregular shapes. The NP suspensions
had dark color (Figure a) and they efficiently absorbed infrared radiation as published
before, thus opening a possibility for efficient PTT.[24] The size of the particles, however, affected the absorption
of light (Figure b).
The largest 300 nm particles absorbed light better in the red and
infrared regions of the spectrum than their smaller counterparts.
Since the pore sizes in BPSi are much smaller than the visible light
wavelength, effective medium approximation can be used to evaluate
optical properties of the NPs.[28] Here,
the NPs are described as a uniform solid with an effective dielectric
permittivity constant calculated as the weighted sum of the dielectric
permittivities of the NP material and the solvent in the pores. Therefore,
higher absorption at long wavelengths is likely to be attributed to
a longer optical path length in large particles. At short wavelengths,
the absorption is limited to narrow nanometer-scale near-surface regions
due to the band gap excitation, making the differences of light absorption
between various sizes less-pronounced.
Figure 2
(a) Typical view of PEG-BPSi-Cy5.5
NPs before size separation.
The scale bar is 200 nm. The inset shows a photograph of 0.2 mg/mL
BPSi-OH dispersion. (b) UV–vis absorption of BPSi-OH NPs with
different particle sizes. (c) Mass losses of BPSi-OH (black), BPSi-NH2-Cy5.5 (red), COOH-BPSi-Cy5.5 (blue), PEG-BPSi-NH2-Cy5.5 (green), and PEG-BPSi-Cy5.5 (magenta) measured by TGA. (d)
Colloidal stability of 140 nm BPSi-NH2-Cy5.5, COOH-BPSi-Cy5.5,
and PEG-BPSi-Cy5.5 in 5% mannitol solution (black), water (red), and
PBS/serum 1:1 volume mixture (blue).
(a) Typical view of PEG-BPSi-Cy5.5
NPs before size separation.
The scale bar is 200 nm. The inset shows a photograph of 0.2 mg/mL
BPSi-OH dispersion. (b) UV–vis absorption of BPSi-OH NPs with
different particle sizes. (c) Mass losses of BPSi-OH (black), BPSi-NH2-Cy5.5 (red), COOH-BPSi-Cy5.5 (blue), PEG-BPSi-NH2-Cy5.5 (green), and PEG-BPSi-Cy5.5 (magenta) measured by TGA. (d)
Colloidal stability of 140 nm BPSi-NH2-Cy5.5, COOH-BPSi-Cy5.5,
and PEG-BPSi-Cy5.5 in 5% mannitol solution (black), water (red), and
PBS/serum 1:1 volume mixture (blue).The surface of BPSi-OH NPs was first modified simultaneously with
amine groups (APTES) and either Cy5.5 (for in vitro) or Cy7.5 (for in vivo) dyes. This resulted in
additional TGA mass loss of 4.1 ± 0.2% compared to BPSi-OH NPs
(Figure c). BPSi-NH2-Cy5.5 aggregated immediately in 5% mannitol solution and
PBS/serum 1:1 mixture due to the positive charge of unreacted amine
groups. In water, the aggregation was also observed for BPSi-NH2-Cy5.5 of all particle sizes after 24 h of incubation (Figures d and S1–S3, Supporting Information). Therefore, the unreacted
amines were capped with succinic anhydrite, which effectively switched
ζ potential to negative values and increased mass loss of COOH-BPSi-Cy5.5
by another 5.1 ± 0.2% compared to BPSi-NH2-Cy5.5 (Figure c). COOH-BPSi-Cy5.5
aggregated less than BPSi-NH2-Cy5.5 in water and 5% mannitol
but still aggregated fast in PBS/serum. Thus, it is essential to further
improve colloidal stability properties of the NPs for long systemic
residence time. To realize this aim, BPSi-NH2-Cy5.5 was
PEGylated with two different PEG molecules as it was previously demonstrated
that such dual-PEG combination provides a longer blood circulation
time than the mono-PEGylation.[14] PEG coating
added 19.2 ± 0.4% of mass loss in TGA measurement compared to
that from BPSi-NH2-Cy5.5. Following PEGylation, unreacted
amine groups were capped with succinic anhydrite to obtain final PEG-BPSi-Cy5.5
(or Cy 7.5) NPs (Figure c). PEG-BPSi-Cy5.5 was the most stable in the PBS/serum mixture;
after 24 h of incubation, it did not show any aggregation (Figures d and S1–S3, Supporting Information).The aggregation
of NPs was further studied with TEM (Figures S4–S6, Supporting Information) after 4 h of incubation
at 37 °C in 50 mM PBS. As shown in Supporting Information, BPSi-NH2-Cy5.5 NPs were heavily aggregated
into large clusters after 4 h. COOH-BPSi-Cy5.5 NPs aggregated somewhat
less and relatively smaller clusters than for BPSi-NH2-Cy5.5
NPs were found together with separate NPs. PEG-BPSi-Cy5.5 NPs showed
no sign of aggregation and remained spread as separate NPs across
the TEM grid. Overall, the results from TEM images are consistent
with those shown in Figure . The positive charge of BPSi-NH2-Cy5.5 NPs induced
the most rapid aggregation and the negative charge of COOH-BPSi-Cy5.5
NPs decreased the rate of agglomeration but could not fully prevent
it, while PEG coating combined with COOH– capping efficiently
suppressed aggregation and kept NPs separated from each other.Depending on the surface coating, BPSi NPs were internalized differently
by cells with similar patterns observed in both CT26 and RAW 264.7
cells. In addition to fast aggregation and subsequent precipitation
on cells, positively charged BPSi-NH2-Cy5.5 NPs were electrostatically
attracted to negatively charged cell membranes. Large aggregates of
BPSi-NH2-Cy5.5 NPs were observed by TEM both outside the
cells and internalized (Figure S14, Supporting Information). The positive charge resulted in higher internalization
into CT26 (Figures and S7–S9, Supporting Information) and RAW 264.7 (Figures S10–S12, Supporting Information), compared to negatively charged COOH-BPSi-Cy5.5
and neutral PEG-BPSi-Cy5.5 NPs. Such a high internalization of BPSi-NH2-Cy5.5 NPs was relatively independent of the particle size
(Figure ). Negatively
charged COOH-BPSi-Cy5.5 NPs had electrostatic repulsion with cell
membranes while still appeared aggregated in cell medium but to a
lesser extent than BPSi-NH2-Cy5.5 NPs. Only few internalized
aggregates of COOH-BPSi-Cy5.5 NPs were found by TEM, and no NPs were
located on the cell membrane (Figure S12, Supporting Information). For COOH-BPSi-Cy5.5 NPs, the size-dependent cellular
internalization was observed: large particles were internalized better
than small ones. The observed trend was attributed to the experimental
conditions, where larger NPs have larger mass per particle, and thus,
they are faster adhered to cell membranes by gravity than smaller
NPs. The PEG coating effectively prevented particles from aggregation.
Only few large 300 nm PEG-BPSi-Cy5.5 were found to be internalized
into CT26 and RAW 264.7 cells possibly due to gravitational force
that governed cell membrane adsorption. The decreased interaction
with the cell membrane of 140 and 200 nm PEG-BPSi-Cy5.5 effectively
reduced their internalization; no internalized 140 nm NPs were found
using TEM (Figure S13, Supporting Information).
Figure 3
Internalization of BPSi-NH2-Cy5.5, COOH-BPSi-Cy5.5,
and PEG-BPSi-Cy5.5 NPs of different sizes into CT26 cells after 24
h of incubation. Cell membranes are shown in green, and NPs are shown
in red.
Internalization of BPSi-NH2-Cy5.5, COOH-BPSi-Cy5.5,
and PEG-BPSi-Cy5.5 NPs of different sizes into CT26 cells after 24
h of incubation. Cell membranes are shown in green, and NPs are shown
in red.In accordance with cell internalization,
both sizes and surface
coatings of BPSi NPs affected cell viability (Figure ). The lowest cell viabilities were found
for positively charged 300 nm BPSi-NH2-Cy5.5 at 0.2 and
0.5 mg/mL concentrations. These NPs internalized the most into cells
and thus impaired their functions accordingly at high concentrations,
which eventually led to cell death. In general, the large 300 nm NPs
decreased cell viability the most for all studied surface coatings.
The decrease was likely to be attributed to the gravitational force
of the NPs in the 2D cell culture system, in which 300 nm particles
adhered more on the cells than the smaller ones and thus impaired
cell viability the most. Low and moderate concentrations up to 0.2
mg/mL were found to be generally safe independent of the coating.
Only BPSi-NH2-Cy5.5 NPs resulted in cell viability slightly
below 80%, while none of the other particles decreased cell viability
by more than 20%, demonstrating good biocompatibility and low toxicity
of BPSi NPs.
Figure 4
Viability of CT26 cells after incubation with BPSi-NH2-Cy5.5, COOH-BPSi-Cy5.5, and PEG-BPSi-Cy5.5 NPs of different
sizes
(mean ± standard deviation, n = 4; significance
analysis *p < 0.05, **p <
0.01, and ***p < 0.001).
Viability of CT26 cells after incubation with BPSi-NH2-Cy5.5, COOH-BPSi-Cy5.5, and PEG-BPSi-Cy5.5 NPs of different
sizes
(mean ± standard deviation, n = 4; significance
analysis *p < 0.05, **p <
0.01, and ***p < 0.001).For in vivo imaging of the organ distribution
profiles, NPs were conjugated with Cy7.5 instead of Cy5.5. Cy7.5 dye
has the excitation/emission profiles in the near-infrared part of
the spectrum; thus, it is more suitable for in vivo imaging than Cy5.5. Since Cy7.5 and Cy5.5 are from the same category
and have the same functional group, the change in the dye to Cy7.5
is not expected to significantly affect physicochemical properties
of the labeled NPs. PEG-BPSi-Cy7.5 NPs of the size of 140, 200, and
300 nm were intravenously injected into CT26 tumor-bearing mice at
a dose of 5 mg/animal. At such a high dose, no obvious toxicity was
observed as animals behaved normally without weight loss up to 2 weeks
postinjection (data not shown). Based on the whole-body imaging from
dorsal view (Figures a and S17, Supporting Information), it
can be seen that PEG-BPSi-Cy7.5 NPs of smaller sizes tended to accumulate
better in tumors. The fluorescence intensity was the highest for 140
nm NPs and the lowest for 300 nm NPs with the signals increasing over
time. The same trend was observed by ex vivo imaging
on excised tumors and other organs (Figure b). In addition, high fluorescent signals
were observed in the liver, intestine, kidneys, and stomach. There
were some fluorescence signals detected in lungs, but no signals were
measured in the spleen. One can notice that there was almost no fluorescence
captured for tissues from the animals treated with 300 nm NPs despite
the “visible” uptake of NPs in certain tissues such
as the liver (e.g., the much darker color of the liver compared to
the control liver) (Figure b). As demonstrated in Figure b, 300 nm NPs absorbed approximately 180 and 80% more
light in the near-infrared region than 140 and 200 nm NPs, respectively.
Thus, both excitation radiation and light emitted by Cy7.5 were likely
to be attenuated by large NPs to a greater extent than by the smaller
counterparts (Figure S19, Supporting Information). Possible aggregation of NPs formed in tissues with higher uptake,
such as the liver and spleen, may further increase the absorption
of light and decrease the emitted fluorescence signals. Therefore,
the calculated total radiance efficiency from different organs and
tumors (Figure c)
could not provide an adequate assessment on the organ biodistribution
of the studied BPSi NPs.
Figure 5
Biodistribution of PEG-BPSi-Cy7.5 NPs of different
sizes using
IVIS after intravenous administration. The injection dose was 5 mg
of NPs per animal. (a) Dorsal view depicting the fluorescence signal
from tumors at 1, 4, and 24 h time points. (b) Ex vivo fluorescence of organs and tumors taken 24 h after injection. (c)
Total radiant efficiency calculated from ex vivo fluorescence
after selecting appropriate ROIs using IVIS software. N = 3.
Biodistribution of PEG-BPSi-Cy7.5 NPs of different
sizes using
IVIS after intravenous administration. The injection dose was 5 mg
of NPs per animal. (a) Dorsal view depicting the fluorescence signal
from tumors at 1, 4, and 24 h time points. (b) Ex vivo fluorescence of organs and tumors taken 24 h after injection. (c)
Total radiant efficiency calculated from ex vivo fluorescence
after selecting appropriate ROIs using IVIS software. N = 3.There are two other difficulties
in addition to light absorption
by the NPs. The first one is the varied thickness of the organs; the
fluorescence signal from the organs may come only from the parts close
to the surface, while deeper light penetration is limited by the absorption
in tissues and the NPs. The second one is the fact that total radiance
efficiency is proportional both to the area of ROI and to the fluorescence
signal in each pixel of the ROI. Thus, some organs with a big ROI
and low background fluorescence can have higher total radiance efficiency
than organs with a small ROI but somewhat higher fluorescence. As
one can see from Figure c, the brain and heart have fluorescence similar to the background
and control animal, but the total radiance efficiency is higher for
the brain than for the heart due to higher ROI area.Despite
the discussed drawbacks of IVIS, qualitative assessment
can still be carried out based on the data from 140 to 200 nm PEG-BPSi-Cy7.5
NPs (Figure b,c).
Clearly, part of the NPs eventually accumulated in the liver and spleen,
which are the organs responsible for eliminating alien bodies from
systemic circulation. Interestingly, high fluorescence was observed
from the stomach, intestine, and kidney. The signals from these tissues
may be a result of some free dyes dissociated from the NPs. It is
also well-known that NPs with ∼100 nm can experience renal
excretion. In mice injected with free Cy7.5, ex vivo images indicate that Cy7.5 accumulated in most of the assessed tissues
with a preferential accumulation in the liver (Figure S21, Supporting Information). In this regard, the
exceptionally high fluorescence signals in the stomach and intestine
are more likely attributed to the PEG-BPSi-Cy7.5 NPs that underwent
the hepatobiliary clearance pathway,[29−31] where the NPs are transported
from the liver to the stomach and small intestine and can be finally
removed from the body by fecal excretion, as reported in other studies.Precise quantification of Si content in major organs and tumors
was further performed using ICP-OES (Figures and S22, Supporting Information). Clearly, the liver and spleen were found to be
the two organs with the highest uptake of PEG-BPSi-Cy7.5 NPs. The
300 nm NPs accumulated the most in the liver, while 140 and 200 nm
NPs showed lower but similar uptake in the liver. A similar trend
was observed in the spleen. Thus, the increase in NP size resulted
in enhanced accumulation in the liver and spleen, known reservoirs
of NPs after systemic administration.[32−34] Interestingly, despite
the observed high fluorescence intensity in kidneys, no Si content
was detected, suggesting the possible release of Cy7.5 from the NPs.
In contrast to the liver and spleen, the smallest 140 nm PEG-BPSi-Cy7.5
showed the highest tumor uptake, achieving 9.5 ± 3.4% of the
injected dose (ID) being retained in tumors (3.5 ± 1.7% ID/g
of tumor). With the increase in NP size, less uptake in tumors was
detected: 5.3 ± 2.3% ID/g and 2.3 ± 5.1% ID/g for 200 and
300 nm NPs, respectively. Overall, the results demonstrated that the
particle size is critical for passive tumor targeting and the small
PEG-BPSi NPs with a size of 140 nm in diameter showed efficient accumulation
in tumors.
Figure 6
Biodistribution of PEG-BPSi-Cy7.5 NPs of different sizes based
on Si content analysis with ICP-OES. Left and right axes show the
total mass of Si in mg in each organ and percent of injected dose
(% ID, ID = 5 mg), respectively. N = 3.
Biodistribution of PEG-BPSi-Cy7.5 NPs of different sizes based
on Si content analysis with ICP-OES. Left and right axes show the
total mass of Si in mg in each organ and percent of injected dose
(% ID, ID = 5 mg), respectively. N = 3.Histological assessments of organs and tumors (Figures and S23, Supporting Information) supported the findings from ICP-OES
analysis. Numerous PEG-BPSi-Cy7.5 NP patches were clearly visualized
in the liver and spleen, possibly taken up by the abundant resident
macrophages in these two organs. The accumulation of PEG-BPSi-Cy7.5
in tumors was less visible in comparison, indicating that the PEG-BPSi
NPs may be distributed more evenly in tumors. Uptake of PEG-BPSi NPs
by Kupffer cells in the liver was also observed. The large patch sizes
in the liver and spleen are expected to attenuate light to an extent
that both the excitation and emission radiations are hindered by high
absorbance in the patches.
Figure 7
Histological examination of vital organs with
H&E staining.
Arrows point to PEG-BPSi-Cy7.5 patches in the spleen, liver, and tumor
tissues. The scale bar is 50 μm.
Histological examination of vital organs with
H&E staining.
Arrows point to PEG-BPSi-Cy7.5 patches in the spleen, liver, and tumor
tissues. The scale bar is 50 μm.
Conclusions
BPSi NPs are efficient absorbers of infrared radiation. This property
makes them an excellent candidate for PTT of cancer, while their porosity
makes it possible to load them with chemotherapeutic drugs opening
a way for a synergistic therapy. In order to achieve sufficiently
high heating to induce cell death, a high number of particles must
reach the tumor. Herein, we examined the influence of size and coating
of BPSi NPs on their in vitro and in vivo behaviors. BPSi NPs without PEG coating aggregated fast in vitro, adhered to the cell membrane and internalized
into cells. The adherence and subsequent internalization were pronounced
more for positively charged 300 nm NPs than that for their smaller
and negatively charged counterparts. PEG coating further improved
biocompatibility of the NPs, demonstrating no toxicity up to 1 mg/mL
concentration and no aggregation up to 24 h in the PBS/serum mixture.
Accordingly, biodistribution of PEG-coated BPSi NPs in tumor-bearing
mice was studied. Intrinsic strong light-absorption properties of
BPSi NPs limited the assessment of their biodistribution by optical
imaging. Instead, the ICP-OES method, based on elemental Si analysis,
successfully quantified the uptake of BPSi NPs in tissues and tumors.
Most of the BPSi NPs were found to accumulate in the liver and spleen.
With the decrease in particle size from 300 to 140 nm, their accumulation
in tumor increased. Nearly 10% injected dose in tumors was achieved
for 140 nm PEG-BPSi-Cy7.5 NPs, equivalent to 0.18 mg/g of tumor. This
amount is known to generate sufficient heat for PTT to induce tumor
cell death.
Authors: Tuomo Nissinen; Simo Näkki; Hanne Laakso; Dalius Kučiauskas; Algirdas Kaupinis; Mikko I Kettunen; Timo Liimatainen; Mervi Hyvönen; Mindaugas Valius; Olli Gröhn; Vesa-Pekka Lehto Journal: ACS Appl Mater Interfaces Date: 2016-11-23 Impact factor: 9.229
Authors: J Salonen; L Laitinen; A M Kaukonen; J Tuura; M Björkqvist; T Heikkilä; K Vähä-Heikkilä; J Hirvonen; V-P Lehto Journal: J Control Release Date: 2005-09-19 Impact factor: 9.776
Authors: Konstantin P Tamarov; Liubov A Osminkina; Sergey V Zinovyev; Ksenia A Maximova; Julia V Kargina; Maxim B Gongalsky; Yury Ryabchikov; Ahmed Al-Kattan; Andrey P Sviridov; Marc Sentis; Andrey V Ivanov; Vladimir N Nikiforov; Andrei V Kabashin; Victor Yu Timoshenko Journal: Sci Rep Date: 2014-11-13 Impact factor: 4.379